First pivotal Phase 3 study of eculizumab commenced in patients with PNH (TRIUMPH). 2005 –Alexion Europe SAS established in Paris, FranceSecond pivotal Phase 3 study of eculizumab in patients with PNH (SHEPHERD) begins. 2006 –Biomanufacturing facility in Smithfield, RI, USA, acquired in anticipa...
在研机构 Alexion Europe SAS 原研机构 Alexion Pharmaceuticals, Inc. 在研适应症 视神经脊髓炎[+13] 非在研适应症 急性肺损伤[+4] 最高研发阶段批准上市 首次获批国家/地区 美国 首次获批日期2018-12-21 378 项与Alexion Pharmaceuticals, Inc. 相关的临床试验 NCT06607627/Not yet recruiting临床3期 An Open-...